Search results
Debasish Banerjee
Research Area(s) / Expertise:
Author
Expertise
Heart FailureHeart Failure ComorbiditiesCardiovascular Kidney MetabolicHeart Failure and Chronic Kidney DiseasePrevention & Chronic ConditionsChronic Kidney DiseaseCardiomyopathies and Cardiac AmyloidosisChronic Heart Failure ManagementInherited and Congenital Cardiac ConditionsCongenital Heart DiseaseMedication Optimisation and TitrationCV Disease in Special PopulationsHeart Failure Services, Prevention and Digital HealthCardiovascular Co-MorbiditiesCardiomyopathies
Michael R Gold
Research Area(s) / Expertise:
Author
Expertise
Heart FailureHeart Failure ComorbiditiesCardiovascular Kidney MetabolicHeart Failure and Chronic Kidney DiseasePrevention & Chronic ConditionsChronic Kidney DiseaseCardiomyopathies and Cardiac AmyloidosisChronic Heart Failure ManagementInherited and Congenital Cardiac ConditionsCongenital Heart DiseaseMedication Optimisation and TitrationCV Disease in Special PopulationsHeart Failure Services, Prevention and Digital HealthCardiovascular Co-MorbiditiesCardiomyopathies
Michael J Koren
Author
Jiunn-Lee Lin
Research Area(s) / Expertise:
Job title: Professor, Chairman (Cardiovascular Center)
Author
Adrian JB Brady
Job title: Consultant Cardiologist and Director of the Hypertension Service
Author
Kazem Rahimi
Author
Added:
3 months ago
Source:
CFR Journal Radcliffe Cardiology
A prespecified, secondary analysis of the MAPLE-HCM trial has shown that aficamten monotherapy provides superior and rapid benefits across multiple domains of disease burden compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).¹ Aficamten is a next-in-class cardiac myosin inhibitor (CMI) designed to reduce myocardial hypercontractility by decreasing…
View more
Navigating Amyloidosis Diagnosis and Referral
Video Series
Author(s):
Nikolaus Marx, Azmee Ghazi, David Quek ,et al
Start date:
Apr 28, 2026
Join leading international and regional experts for an in-depth clinical session focused on the evolving role of semaglutide in the management of cardiometabolic disease. As obesity is increasingly recognised as a chronic, progressive driver of cardiovascular risk, this webinar will explore how to transition from traditional weight-management models to a cardioprotective standard of care tailored…
View more
David Thompson
Research Area(s) / Expertise:
Job title: Professor of Nursing
Author